Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (271-280 of 306) with videos related to

Pageof 31
Sort By:
Annals of Hepatology|March 13, 2026
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. citiesJeffrey V Lazarus, Trenton M White, Melina Manolas, et al.
The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Hepatology Communications|May 7, 2025
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United StatesJeffrey V Lazarus, Trenton M White, Alina M Allen, et al.
Hepatology Communications|July 19, 2021
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Mazen Noureddin, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Digestive Diseases and Sciences|March 24, 2018
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune HepatitisCumali Efe, Haider Al Taii, Henriette Ytting, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 30, 2018
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic SteatohepatitisEric J Lawitz, Angie Coste, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Hepatology Communications|February 15, 2023
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling studyRegino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2022
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR TrialsVincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, et al.
Pageof 31

Showing results (271-280 of 306) with videos related to

Sort By:
Pageof 31
Annals of Hepatology|March 13, 2026
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. citiesJeffrey V Lazarus, Trenton M White, Melina Manolas, et al.
The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Hepatology Communications|May 7, 2025
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United StatesJeffrey V Lazarus, Trenton M White, Alina M Allen, et al.
Hepatology Communications|July 19, 2021
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Mazen Noureddin, et al.
Lancet (London, England)|November 14, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyMazen Noureddin, Stephen A Harrison, Rohit Loomba, et al.
Digestive Diseases and Sciences|March 24, 2018
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune HepatitisCumali Efe, Haider Al Taii, Henriette Ytting, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 30, 2018
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic SteatohepatitisEric J Lawitz, Angie Coste, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Hepatology Communications|February 15, 2023
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling studyRegino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2022
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR TrialsVincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, et al.
Pageof 31